Teva Pharmaceutical Industries R&D Day 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone. Thank you for coming to Teva's R&D Day 2026. We are very happy to welcome all of you here to New York City. For those of you joining in virtually, we would like to thank you as well. Before we get started, just a few housekeeping items. For those of you here in person, please turn off or silence your mobile devices. That is very important. We will have time for Q&A after the presentations, and we ask that you please hold your questions until then. We will have plenty of time for questions. For those joining the webcast, you will be able to submit questions via the webcast as well, and there will be instructions on the platform at that time. Most importantly now, please note that today's presentations and Q&A include forward-looking statements, including about our pipeline, clinical programs, and regulatory timelines.
These involve risks and uncertainties, and actual results may differ materially. Risk factors are described in our latest Form 10-K, Forms 10-Q, and earnings press release. Statements are made as of today, and we undertake no obligation to update them. We may also discuss certain non-GAAP measures. A reconciliation to the most directly comparable GAAP measure can be found on our website. Quickly, let me walk you through what to expect on the agenda today. We will start with Richard Francis, who will put today's discussion in the broader context of Teva as a leading biopharmaceutical company and where we are in our Pivot to Growth strategy, and where we see opportunity ahead. Eric Hughes will then come and take you inside what we mean by high-velocity biopharma, how the way we operate, make decisions, and execute is enabling us to move with greater speed and focus.
Steffen Nock and David Gardiner will go deeper into our high-value pipeline, including the early and late-stage programs and assets. We will then turn to unlocking more value with Chris Fox, looking at how we are maximizing the potential of our existing assets and creating additional opportunities for patients and for Teva. Eli Kalif will then walk us through the big picture of Teva's current and future financial outlook and acumen. Finally, Richard Francis will bring it all together, including what this portfolio and pipeline mean for Teva. Then we will have the Q&A session. With that, it is my pleasure to introduce Teva CEO, Richard Francis.
Thank you, Chris. Welcome, everybody. Thank you so much for coming here today, so early in the day, to Teva's first R&D Day. It is interesting because I was on this stage 3 and a half years ago, and actually some of you were in the audience, so welcome back, where we launched the Pivot to Growth strategy, a strategy that was put in place to transform Teva from a pure-play generics company to a world-leading biopharma company. That strategy became very much our North Star. Everything we did every day, every week, every month was focused on that strategy. It was a very specific strategy. It was very detailed. What I would say about that, there is good and bad in that. The good is you know exactly what to do, when to do it.
The bad is everybody else knows exactly what you're planning to do and when you're planning to do it. The ability to be evaluated and measured is really clear. But we're okay with that. We've been okay with that on this transformation, and we'll be okay with that going forward. Now, when we talk about what we're going to go through today, it's very much that transformation from a pure-play generics to a world-leading biopharma company. While that statement, I think, was a challenging statement to communicate three and a half years ago, I think, and I'll explain why, it's less so today. You're going to hear about our pipeline and the transformation of our pipeline.
The fact that whether it's early or late stage, you're going to get some insights from Eric as to how we've done it so quickly, and our approach to our R&D, which I think is a slightly different strategy from others, and what that has actually given us in terms of results. Then you can actually see the value that we create out of that pipeline, because having a pipeline and bringing it to market is one thing, but being able to maximize it and optimize it is really important. And we give you proof points of what we've done and what we will do. Now, when we think about this strategy, as I said, it's our North Star. And this is the slide that I presented three and a half years ago on this stage.
This is the exact slide, which is why it looks a bit dated and not as fancy as the new slides. But I tell you this, and I show you this, and many of you I talked to on a regular basis, I walk through all of these pillars every time. This is how we execute and operate at Teva. We have clear North Star, we know where we're going, we have a clear plan to get there, and we execute relentlessly across all of these pillars. Operations, we love. We love the execution. We love the focus on moving things forward. And you'll see that today. Now, this is what we set out to do. And as I said, when I presented that three and a half years ago, it was very detailed, but it did have a level of skepticism from the audience, I remember.
Where we ended up. Well, I wouldn't just say we've met our commitments. I'd argue that we've over-delivered significantly on many of these commitments. And I remind you that there was real ambition in what we set out to do. One of the things you're going to hear about today is how we did it, which I call the Teva way. It's about our people and our culture. To move a company so quickly to where we have, to do so much in such a short space of time, you can only do if you have great people and a great culture. And you'll hear that from all of the people on stage today. But if you look about just the numbers, because I can talk about things, but I think I've got an audience of people who are very much focused on the numbers.
The numbers are, in 2022, we ended the year with innovative sales of $1.3 billion. We are now going to end the year with $3.8 billion to $3.92 billion. AUSTEDO was doing less than $1 billion in 2022. It is going to do $2.5 billion this year, which is a year ahead of schedule, which was seen as a stretch. In the meantime, we have launched UZEDY, and we have just recently launched WELTRUZA, our long-acting olanzapine. In the meantime, despite the capital constraints we have had with the necessity to pay down debt, we have allocated capital, and we have done two deals. We have done a deal with Emalex with ecopipam, and we have done a deal with BioXcel with dexmedetomidine. At the same time, on step-up innovation, something which people really questioned us about, can you drive innovative pipeline?
We have taken a pipeline, we have radically changed it, we have 10 assets in the pipeline, and we move at pace. Pace is really key. You will see the appetite we have to move fast will continue. We have had six positive clinical readouts, all in the space of three and a half years. When it came to our generics business, that was one that had a lot of discussion three and a half years ago. Now, not a lot less, which sometimes disappoints me, because the radical change in that business has occurred. We started with stabilizing the business, and now we have changed the portfolio completely. We had six biosimilars in 2023. We have 32 now. We have 15 in the market, and we keep doing more deals and more partnerships. We have changed the whole portfolio makeup.
When it comes to focus the business, this was all about capital allocation. Put the capital where it gets the best return, best short, medium, and long-term return. By the way, to do that in a capital-constrained company means you have to have real discipline and make real choices. To drive this pipeline, to drive these innovative products, we had to allocate capital, which means you had to take it from somewhere else. That allowed prioritization. That allowed focus within the organization. You are starting to see that, but some of the things that have come out, we committed to being investment grade by the end of 2027. We have already done that a year ahead of schedule. Instead of a year ahead of schedule.
One I missed, our biosimilar business, we said we are going to double that by 2027, and we have doubled it by the end of 2026. From a free cash flow point of view, the company has been transformed. I would argue, and I would ask you maybe, to look at the free cash flow as the presentation goes on, because this is something people need to start to understand and recognize. That is what we did. That has been driven in a very short period of time. What does that mean? Where are we on this journey to becoming a biopharma company? I am very much a numbers guy, so as much as I will talk about things and highlight things in a strategic way, it all comes back to the numbers, and the numbers will always tell you the truth.
The reality is, we have transformed this company. It is no longer a pure-play generics company. It is a biopharma company, I would say a world-leading biopharma company already. Our innovative revenue is not only doubled, it has almost gone up three times to $3.92 billion at the end of this year. The growth trajectory of that, you will see through the presentation, is significant, and the amount we have in our pipeline is significant. That pipeline can deliver over $10 billion of peak sales. What you will also see is the probability of that pipeline maturing actually coming to market, and that is an important part to take into account. How have we done this?
I often get asked, "How do we do this in such a short space of time?" I would argue it is the right people in the right place with the right culture and the right plan, and then you just execute. There are some subtleties to it, and maybe I will talk to you through a bit about how we have done that. You have heard this term already, a high-velocity biopharma company. What does that mean? I have worked in both biotech, I have worked in both startup, and I have worked in big pharma, and they all have appealing attributes. What you will find at Teva is we have combined those two. The speed and agility of a biotech company, but the scale, the capability, and the discipline of a world-leading biopharma company, we brought them together. What does that mean? It means we create a different approach to how we run the business.
From R&D, excuse me, you will hear from Eric about his different approach to R&D, which is based on the fundamentals of picking assets with a high probability of success based on either the target has been validated, we know the mechanism of action. Whether that science comes internally or externally, we are agnostic. We do not believe in-house is better than external. We just focus on the asset. The other part, which is critical, is accelerated development. Having the right product in your pipeline is only valuable if you get it to market as soon as possible. Because then you can just start to generate revenue, which means then you can start the cycle again. When it comes to the middle part, decisive decision-making and capital allocation, we do this across the business regularly. We do not have an end-of-year AOP where we allocate capital. It is real-time. When Eric turns over some data, we go straight away there and then, and we allocate capital, which means we have to take it from somewhere else.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProKeep exploring
